Evidence map›Paper›PMID 36193672›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2022

Effect of baseline resting heart rate on the risk of all-cause death in Chinese patients with hypertension.

Xia Yulong, Fan Fangfang, Huo Ya, Wei Yaping, Huang Meiqing, Zhang Yan, Li Jianping, Liu Lishun, Zhou Jing, Huo Yong

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Xia YulongDepartment of Cardiovascular Disease, Peking University First Hospital, Beijing, China.ORCID 0000-0002-2998-2074
Fan FangfangDepartment of Cardiovascular Disease, Peking University First Hospital, Beijing, China.
Huo YaState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.
Wei YapingKey Laboratory of Precision Nutrition and Food Quality, Ministry of Education, Department of Nutrition and Health, College of Food Sciences and Nutritional Engineering, China Agricultural University, Beijing, China.
Huang MeiqingShenzhen Evergreen Medical Institute, Shenzhen, China.
Zhang YanDepartment of Cardiovascular Disease, Peking University First Hospital, Beijing, China.
Li JianpingDepartment of Cardiovascular Disease, Peking University First Hospital, Beijing, China.
Liu LishunShenzhen Evergreen Medical Institute, Shenzhen, China.
Zhou JingDepartment of Cardiovascular Disease, Peking University First Hospital, Beijing, China.
Huo YongDepartment of Cardiovascular Disease, Peking University First Hospital, Beijing, China.ORCID 0000-0002-5407-8773
Peking University · CNChina Pharmaceutical University · CNMinistry of Education · SAShenzhen Genoimmune Medical Institute · CNUniversity Town of Shenzhen · CN

Funding

Department of Science and Technology of Guangdong Province 2020B121202010Economic, Trade and Information Commission of Shenzhen Municipality 20170505160926390Economic, Trade and Information Commission of Shenzhen Municipality 20170505161556110Economic, Trade and Information Commission of Shenzhen Municipality 201705051617070National Key Research and Development Program 2016YFE0205400National Key Research and Development Program 2017YFC1307704National Key Research and Development Program 2018ZX09301034003National Key Research and Development Program 2018ZX09739010Science and Technology Planning Project of Guangzhou, China 201707020010Science, Technology and Innovation Committee of Shenzhen GJHS20170314114526143Science, Technology and Innovation Committee of Shenzhen JSGG20180703155802047
6 · The paper itself

Abstract

The aim of this study was to investigate the association between baseline resting heart rate (RHR) and all-cause death in the China Stroke Primary Prevention Trial (CSPPT). A post hoc analysis was conducted using data from 20,648 hypertensive adults without cardiovascular disease in the CSPPT and with baseline RHR data available. Over a median follow-up duration of 4.5 years, the baseline RHR and risk for all-cause death had a nonlinear relationship. The risk of all-cause death was higher in participants with an RHR ≥85 bpm (hazard ratio 1.42; 95% confidence interval 1.03-1.96, p = .031) than in those with a baseline RHR of 75-80 bpm. The effect of RHR on all-cause death during the treatment period was modified by the folate level (p = .020) and systolic blood pressure (SBP) during treatment(p = .056). The effect of RHR on the risk of all-cause death was stronger when the folate level was low than when it was high; the risk was higher when the RHR was < 75 bpm or ≥80 bpm than when it was 75-80 bpm. RHR had a greater effect on the risk of all-cause death when SBP during treatment was well controlled than when it was not; again, the risk was higher when the RHR was < 75 bpm or ≥80 bpm than when it was 75-80 bpm. A higher baseline RHR resulted in an increased risk of all-cause mortality in Chinese adults with hypertension but no history of stroke or myocardial infarction.

Indexed as

HypertensionMyocardial InfarctionStrokeAdultBlood PressureFolic AcidHeart RateHumansRisk FactorsFolic Acidantihypertensive therapyAsian patientsclinical trialshypertension-generalrisk assessment

Identifiers

PMID36193672
PMCPMC9659881
OpenAlexW4300860665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.